Peregrine announces PS-targeting antibodies enhance anti-tumor activity of PD-L1
Peregrine Pharmaceuticals announced preclinical study data demonstrating that phosphatidylserine-targeting antibodies similar to bavituximab are able to enhance the anti-tumor activity of anti-PD-L1 therapy in a model of triple negative breast cancer. October 24, 2016